European Psychiatry - Volume 41 - April 2017

830 / 916

S826 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846
apy, thus reducing the side effects, although in our sample 8%which
has occurred was removed therefrom.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1285
Combination of clozapine and
aripiprazole once-monthly in
resistant schizophrenia. A review of a
clinical case
M. Palomo Monge ∗, M.F. Tascon Guerra , J.F. Calvo Mauri ,
P. Padilla Romero , A. Duque Domínguez , S. Díaz Conde ,
M.F. Alcocer Lanza , B. Lara de Lucas , R. Ochoa Blanco
1 Hospital Nuestra Se˜nora del Prado, Psychiatry, 45600, Spain
2 Hopital provincial de Ávila, Psychiatry, Ávila, Spain
3 Centro de Rehabilitación Psicosocial y Laboral, Psichologyst, 45600,
Spain
4 Hospital Nuestra Se˜nora del Prado, family and community
medicine, 45600, Spain
∗ Corresponding author.
Introduction We report the successful management of a 49-year-
old woman with an initial diagnosis of schizoaffective disorder
transitioned to resistant schizophrenia. First contact with our
psychiatrist service in 2000; referring problems with treatment
adherence and occasional toxic abuse, she underwent 15 admis-
sions in acute adult psychiatric hospitalisation units since then (last
discharge March, 2015), and a one-year stay (2012–2013) in an
adult mid-term mental health unit. She is currently followed-up
throughout the major mental-health outpatient visits program.
Aims The patient was prescribed paliperidone 6mg 2-0-0, oxcar-
bazepine 600mg 1-0-1 and clonazepam 0.5mg 1-0-1 during the
last 2 months.
Methods Due to lack of treatment adherence and toxic abuse
she suffered a psychotic decompensation in May 2015. She was
then prescribed clozapine 200mg 1-0-2, boosted with aripipra-
zole 400mg once monthly. The adjunction of aripiprazole once
monthly (AOM) was intended to improve treatment adherence, and
to supplement the psychotic control of clozapine without entail-
ing a worsening of therapy tolerability. The patient was monitored
during 5months in our unit.
Results We observed a positive psychopathological evolution of
the patient, which allowed us to re-evaluate the initial diagnostic,
ascribing the previous mood fluctuations to toxic consumption.
Conclusion Previous works have been published about the com-
bination of clozapine and oral aripiprazole for the treatment of
resistant schizophrenia, but, as far as we know, this is the first
repost of the combined use of clozapine and AOM. Based on our
results, this antipsychotic combination resulted in a psychopatho-
logical improvement of the patient, with good tolerability.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1286
Treatment patterns in schizophrenia:
Clinical case of successful
management with a series of long
acting injectable antipsychotics
M. Palomo Monge ∗, J.F. Calvo Mauri , M.F. Tascon Guerra ,
A. Duque Domínguez , S. Díaz Conde , P. Padilla Romero ,
M.F. Alcocer Lanza , R. Ochoa Blanco , B. Lara de Lucas
1 Hospital Nuestra Se˜nora del Prado, Psychiatry, 45600, Spain
2 Hospital Nuestra Se˜nora del Prado, Psychiatry, Spain
3 Hospital Provincial de Ávila, Psychiatry, Ávila, Spain
4 Centro de Rehabilitación Psicosocial y Laboral, psychologist, 45600,
Spain
5 Hospital Nuestra Se˜nora del Prado, family and community
medicine, 45600, Spain
∗ Corresponding author.
Introduction We report the successful management of a 57-year-
old woman with a 20 year diagnostic of paranoid schizophrenia
(first visit November, 1995). She presented several comorbidities
(arterial hypertension, diabetes mellitus and morbid obesity), with
a history of five previous hospitalizations (1995, 2012, January and
May 2014, and April 2016).
Aims/methods The patient was always prescribed depot antipsy-
chotics: she was treated for 14 years with Zuclopentixol depot
(discontinued due to dermic adverse reactions and weight gain).
After a period with oral paliperidone (from 2012 until 2013) and
due to lack of adherence to oral therapy, in August 2013 she was
prescribed paliperidone palmitate. The treatment was discontin-
ued after nine months (May 2014) due to weight gain, a significant
increase of serum prolactin levels and two psychotic relapses that
led to hospital admissions.
Results She was then prescribed Fluphenazine decanoate depot
for one year and 4months, but she was switched to Aripiprazole
once monthly (AOM) in September 2015 to avoid metabolic syn-
drome.
Conclusions Non-personalized antipsychotic treatment in a
patient with a complicated comorbidity history can result in lack of
compliance and a risk of relapse, and in a worsening of her medical
conditions, with the consequential negative impact in her function-
ing and quality of life. Based on our results, the treatment with AOM
resulted in a positive evolution of the patient, with a good tolerabil-
ity profile, in an improvement of treatment-caused adverse events
(weight loss, and prolactin serum levels normalization); all factors
that enable treatment adherence and good clinical response.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1287
A thalamo-cortical genetic
co-expression network is associated
with thalamic functional connectivity
linked with familial risk for
schizophrenia
R. Passiatore ∗, L.A. Antonucci , P. Di Carlo , M. Papalino ,
A. Monda , P. Taurisano , A. Bertolino , G. Pergola , G. Blasi
1 University of Bari “Aldo Moro”, Department of Basic Medical
Sciences, Neuroscience and Sense Organs, Bari, Italy
2 University of Bari “Aldo Moro”, Department of Educational Sciences,
Psychology and Communication Sciences, Bari, Italy
3 Bari University Hospital, Psychiatry Unit, Bari, Italy
∗ Corresponding author.
Introduction The genetic architecture of schizophrenia is based
on polygenic trajectories. Indeed, genes converge on molecular
co-expression pathways, which may be associated with heritable
characteristics of patients and their siblings, called intermediate
phenotypes, such as prefrontal anomalies and thalamic dysconnec-
tivity during attentional control
Objectives Here, we investigated in healthy humans association
between co-expression of genes with coordinated thalamo-
prefrontal (THA-PFC) expression and functional connectivity
during attentional control.
Methods We used Brainspan dataset to characterize a coordi-
nated THA-PFC expression gene list by correlating post-mortem
gene expression in both areas (Kendall’s Tau>.76, Bonferroni
P < .05). Then, we identified a PFC co-expression network1 and
tested all gene sets for THA-PFC and PGC loci nrichments